News & Analysis on Biopharmaceutical Development & Manufacturing
By Melissa Fassbender
- Last updated on
The sixty-two completed KUBio modules will span approximately 2,400m2 when assembled, and will contain several 2,000L single-use bioreactors – making it the largest volume of single-use cell culture capacity in Asia, according to the company.
JHL will manufacture biosimilars and monoclonal antibodies (mAbs) for late–stage clinical trials and commercial supply at the facility. The facility will also provide process development and manufacturing services.